SEC Filing | Yield10 Bioscience, Inc.

View:

SEC FORM 3 SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

GILES EDWARD M

(Last)

(First)

(Middle)

C/O METABOLIX, INC.

21 ERIE STREET

(Street)

CAMBRIDGE

02139

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
11/09/2006

3. Issuer Name and Ticker or Trading Symbol
METABOLIX, INC. [ MBLX ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	48,663	D
Common Stock	81,730	I	By Isles Capital, L.P.⁽¹⁾
Common Stock	73,932	I	By Metabolix Common 2005 GRAT⁽¹⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Series A Preferred Stock	⁽²⁾	⁽²⁾	Common Stock	60,000	⁽²⁾	D
Series B Preferred Stock	⁽²⁾	⁽²⁾	Common Stock	38,000	⁽²⁾	D
Series C Preferred Stock	⁽²⁾	⁽²⁾	Common Stock	46,000	⁽²⁾	D
Series D Preferred Stock	⁽²⁾	⁽²⁾	Common Stock	43,000	⁽²⁾	D
Series E Preferred Stock	⁽²⁾	⁽²⁾	Common Stock	10,000	⁽²⁾	I	By Metabolix 2006 GRAT I⁽¹⁾
Series F Preferred Stock	⁽²⁾	⁽²⁾	Common Stock	23,149	⁽²⁾	I	By Metabolix 2006 GRAT I⁽¹⁾
Series G Preferred Stock	⁽²⁾	⁽²⁾	Common Stock	46,300	⁽²⁾	I	By Metabolix 2006 GRAT I⁽¹⁾
Series 04 Preferred Stock	⁽²⁾	⁽²⁾	Common Stock	80,776	⁽²⁾	D
Series 05 Preferred Stock	⁽²⁾	⁽²⁾	Common Stock	28,185	⁽²⁾	I	By Metabolix 2006 GRAT I
Warrant (right to buy)	⁽³⁾	11/04/2008	Common Stock	107,222	0.12	D
Warrant (right to buy)	⁽³⁾	04/12/2007	Common Stock	42,001	13.21	D
Warrant (right to buy)	⁽³⁾	06/10/2008	Common Stock	11,609	13.21	D
Warrant (right to buy)	⁽³⁾	04/12/2007	Common Stock	22,972	13.21	D
Warrant (right to buy)	⁽³⁾	11/04/2008	Common Stock	6,620	0.12	D
Warrant (right to buy)	⁽³⁾	04/12/2007	Common Stock	1,675	13.21	D
Warrant (right to buy)	⁽³⁾	06/10/2008	Common Stock	1,634	13.21	D
Warrant (right to buy)	⁽³⁾	04/12/2007	Common Stock	1,675	13.21	D
Warrant (right to buy)	⁽³⁾	01/15/2009	Common Stock	3,038	0.12	D
Warrant (right to buy)	⁽³⁾	11/04/2008	Common Stock	13,331	0.12	D
Series 04 Preferred Stock	⁽²⁾	⁽²⁾	Common Stock	11,770	⁽²⁾	I	By Isles Capital, L.P.⁽¹⁾
Series 05 Preferred Stock	⁽²⁾	⁽²⁾	Common Stock	7,000	⁽²⁾	I	By Isles Capital, L.P.⁽¹⁾
Series 04 Preferred Stock	⁽²⁾	⁽²⁾	Common Stock	165,560	⁽²⁾	I	By Metabolix Preferred 2005 GRAT⁽¹⁾
Series 04 Preferred Stock	⁽²⁾	⁽²⁾	Common Stock	52,366	⁽²⁾	I	By Metabolix 2006 GRAT I⁽¹⁾
Series 04 Preferred Stock	⁽²⁾	⁽²⁾	Common Stock	160,000	⁽²⁾	I	By Metabolix 2006 GRAT II

Explanation of Responses:

1. The reporting person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest, if any.

2. The Issuer's preferred stock will automatically be converted into Common Stock on a .8173-for-1 basis upon the closing of the Issuer's initial public offering.

3. These warrants are fully vested and exercisable.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Sarah P. Cecil, attorney-in-fact	11/09/2006
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Exhibit 24


POWER OF ATTORNEY

	KNOW ALL MEN BY THESE PRESENTS, that the
undersigned hereby constitutes and appoints James J.
Barber, Thomas G. Auchincloss, Jr., Aninda Katragadda,
Sarah Cecil, Christopher J. Denn, John M. Mutkoski,
and Robert E. Puopolo and any one of them acting
singly, the true and lawful attorneys-in-fact and
agents, with full power of substitution and
resubstitution, for the undersigned and in the
undersigned's name, place and stead, in any and all
capacities (until revoked in writing) to execute for
and on behalf of the undersigned, in any and all of
the undersigned's capacities, any and all statements
on Forms 3, 4 and 5 with respect to the undersigned's
holdings of and transactions in securities issued by
Metabolix, Inc. (the "Company") in accordance with
Sections 16(a) of the Securities Exchange Act of 1934,
as amended (the "Exchange Act"), and any and all
regulations promulgated thereunder, and to file the
same, with all exhibits thereto, and any other
documents in connection therewith, with the Securities
and Exchange Commission, and with any other entity
when and if such is mandated by the Exchange Act or by
the By-laws of the National Association of Securities
Dealers, granting unto said attorneys-in-fact and
agents full power and authority to do and perform each
and every act and thing requisite and necessary fully
to all intents and purposes as the undersigned might
or could do in person thereby ratifying and confirming
all that said attorneys-in-fact and agents, or their
substitute or substitutes, may lawfully do or cause to
be done by virtue hereof.

	This Power of Attorney shall remain in full force
and effect until the undersigned is no longer required
to file Forms 3, 4 and 5 with respect to the
undersigned's holdings of and transactions in
securities issued by the Company, unless earlier
revoked by the undersigned in a signed writing
delivered to the foregoing attorneys-in-fact.

	IN WITNESS WHEREOF, this Power of Attorney has
been signed as of October 23, 2006.


Signature:	/s/ Edward M. Giles

Name:  Edward M. Giles